Bristol Myers Squibb expands Alzheimer's psychosis drug trial after site irregularities

statnews.com

Bristol Myers Squibb will enroll more patients in a key Alzheimer's psychosis drug trial after discovering execution irregularities at some sites. The company consulted the FDA, leading to an independent analysis. The data monitoring committee recommended continuing the study with more participants. This decision follows an interim efficacy and safety review. Bristol shares saw a slight increase in premarket trading.


With a significance score of 2, this news ranks in the top 25% of today's 31993 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Bristol Myers Squibb expands Alzheimer's psychosis drug trial after site irregularities | News Minimalist